Michael Benatar

List of Publications by Year
in descending order

149 papers	16,633 citations	31976 53 h-index	16650 123 g-index
161 all docs	161 docs citations	161 times ranked	15582 citing authors

#	Article	IF	Citations
1	Occupational lead exposure and survival with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2023, 24, 100-107.	1.7	2
2	Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain, 2022, 145, 27-44.	7.6	38
3	Harnessing the power of the electronic health record for <scp>ALS</scp> research and quality improvement: <scp>CReATe CAPTUREâ€ALS</scp> and the <scp>ALS</scp> Toolkit. Muscle and Nerve, 2022, 65, 154-161.	2.2	4
4	Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. Neurology, 2022, 98, .	1.1	51
5	Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis. European Journal of Neurology, 2022, 29, 990-999.	3.3	14
6	Revealing the Mutational Spectrum in Southern Africans With Amyotrophic Lateral Sclerosis. Neurology: Genetics, 2022, 8, e654.	1.9	10
7	Phase <scp>2B</scp> randomized controlled trial of <scp>NP001</scp> in amyotrophic lateral sclerosis: Preâ€specified and post hoc analyses. Muscle and Nerve, 2022, 66, 39-49.	2.2	16
8	Pre-symptomatic spinal muscular atrophy: a proposed nosology. Brain, 2022, 145, 2247-2249.	7.6	11
9	Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 517-526.	1.7	13
10	Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics, 2022, 19, 1248-1258.	4.4	46
11	Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: a new diagnostic entity. Brain, 2022, 145, 3500-3508.	7.6	17
12	Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis. Neurology, 2021, 96, e853-e865.	1.1	97
13	International Consensus Guidance for Management of Myasthenia Gravis. Neurology, 2021, 96, 114-122.	1.1	272
14	To Zoom or Not to Zoom: The Should I Travel Index Revisited during the Coronavirus Disease Pandemic. Annals of Neurology, 2021, 89, 1057-1058.	5.3	1
15	Challenges and opportunities for Multi-National Investigator-Initiated clinical trials for ALS: European and United States collaborations. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 419-425.	1.7	4
16	Application of a bioinformatic pipeline to RNA-seq data identifies novel virus-like sequence in human blood. G3: Genes, Genomes, Genetics, 2021, 11, .	1.8	4
17	FGF23, a novel muscle biomarker detected in the early stages of ALS. Scientific Reports, 2021, 11, 12062.	3.3	7
18	Repeats expansions in ATXN2, NOP56, NIPA1 and ATXN1 are not associated with ALS in Africans. IBRO Neuroscience Reports, 2021, 10, 130-135.	1.6	6

#	Article	IF	Citations
19	Humoral response to neurofilaments and dipeptide repeats in ALS progression. Annals of Clinical and Translational Neurology, 2021, 8, 1831-1844.	3.7	8
20	Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis. EMBO Molecular Medicine, 2021, 13, e12595.	6.9	13
21	Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design. Neurology: Clinical Practice, 2021, 11, e472-e479.	1.6	0
22	Epigenetic Small Molecules Rescue Nucleocytoplasmic Transport and DNA Damage Phenotypes in C9ORF72 ALS/FTD. Brain Sciences, 2021, 11, 1543.	2.3	5
23	Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS). Neurology: Clinical Practice, 2021, 11, e472-e479.	1.6	1
24	CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 1296-1306.	3.7	26
25	Incremental Gains in the Battle against ALS. New England Journal of Medicine, 2020, 383, 979-980.	27.0	3
26	Yes, we can: Neuromuscular examination by telemedicine. Muscle and Nerve, 2020, 62, E83-E85.	2.2	9
27	Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America. BMJ Open, 2020, 10, e037909.	1.9	12
28	Dipeptide repeat proteins inhibit homology-directed DNA double strand break repair in C9ORF72 ALS/FTD. Molecular Neurodegeneration, 2020, 15, 13.	10.8	58
29	Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology, 2020, 95, e59-e69.	1.1	119
30	Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 538-548.	1.7	76
31	Pediatric Cancer Variant Pathogenicity Information Exchange (PeCanPIE): a cloud-based platform for curating and classifying germline variants. Genome Research, 2019, 29, 1555-1565.	5.5	28
32	Editorial: We may need large trials to find treatments for neurodegenerative diseases. Clinical Trials, 2019, 16, 120-121.	1.6	0
33	Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurology, The, 2019, 18, 259-268.	10.2	139
34	ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2019, 10, 293.	2.4	54
35	Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 303-309.	1.7	53
36	Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology, 2019, 92, e1610-e1623.	1.1	105

#	Article	IF	Citations
37	Longâ€term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle and Nerve, 2019, 60, 14-24.	2.2	162
38	Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein. Nature Neuroscience, 2019, 22, 1966-1974.	14.8	101
39	Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. Muscle and Nerve, 2019, 59, 404-410.	2.2	56
40	An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis. JCI Insight, 2019, 4, .	5.0	11
41	Ocular Myasthenia. Neurologic Clinics, 2018, 36, 241-251.	1.8	50
42	Increased cerebral functional connectivity in ALS. Neurology, 2018, 90, e1418-e1424.	1.1	26
43	Impaired corticomuscular and interhemispheric cortical beta oscillation coupling in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2018, 129, 1479-1489.	1.5	36
44	Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology, 2018, 90, e565-e574.	1.1	99
45	The state of clinical research in neurology. Neurology, 2018, 90, e1347-e1354.	1.1	14
46	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
47	Identification of compound heterozygous variants in OPTN in an ALS-FTD patient from the CReATe consortium: a case report. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 469-471.	1.7	15
48	Learning from the past: reflections on recently completed myasthenia gravis trials. Annals of the New York Academy of Sciences, 2018, 1412, 5-13.	3.8	11
49	Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 555-561.	1.7	37
50	Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Annals of Neurology, 2018, 84, 130-139.	5.3	182
51	Medical and surgical treatment for ocular myasthenia. The Cochrane Library, 2017, 2017, CD005081.	2.8	24
52	Urinary p75 ^{ECD}. Neurology, 2017, 88, 1137-1143.	1.1	84
53	Phosphorylated neurofilament heavy chain: A biomarker of survival for <scp>C9ORF</scp>72â€associated amyotrophic lateral sclerosis. Annals of Neurology, 2017, 82, 139-146.	5.3	88
54	Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	12.4	179

#	Article	IF	Citations
55	Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 153-174.	1.7	607
56	Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 256-264.	1.7	17
57	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986.	10.2	472
58	Rituximab as treatment for anti-MuSK myasthenia gravis. Neurology, 2017, 89, 1069-1077.	1.1	185
59	A C9ORF72 BAC mouse model recapitulates key epigenetic perturbations of ALS/FTD. Molecular Neurodegeneration, 2017, 12, 46.	10.8	22
60	Abnormal expression of homeobox genes and transthyretin in C9ORF72 expansion carriers. Neurology: Genetics, 2017, 3, e161.	1.9	12
61	Altered cortical betaâ€band oscillations reflect motor system degeneration in amyotrophic lateral sclerosis. Human Brain Mapping, 2017, 38, 237-254.	3.6	58
62	How Neurologists and Neuro-Ophthalmologists Think. Journal of Neuro-Ophthalmology, 2016, 36, 4-5.	0.8	1
63	Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial. Muscle and Nerve, 2016, 53, 363-369.	2.2	113
64	Getting Rid of Weakness in the ICU: An Updated Approach to the Acute Management of Myasthenia Gravis and Guillain-BarrÃ© Syndrome. Seminars in Neurology, 2016, 36, 615-624.	1.4	23
65	Increased functional connectivity common to symptomatic amyotrophic lateral sclerosis and those at genetic risk. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 580-588.	1.9	82
66	Presymptomatic ALS genetic counseling and testing. Neurology, 2016, 86, 2295-2302.	1.1	47
67	Randomized Trial of Thymectomy in Myasthenia Gravis. New England Journal of Medicine, 2016, 375, 511-522.	27.0	695
68	A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology, 2016, 87, 57-64.	1.1	106
69	Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle and Nerve, 2016, 53, 165-168.	2.2	24
70	International consensus guidance for management of myasthenia gravis. Neurology, 2016, 87, 419-425.	1.1	736
71	Reply. Annals of Neurology, 2016, 79, 334-334.	5.3	2
72	ALS biomarkers for therapy development: State of the field and future directions. Muscle and Nerve, 2016, 53, 169-182.	2.2	85

#	Article	IF	Citations
73	C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cells. Experimental Neurology, 2016, 277, 171-177.	4.1	21
74	To travel or not to travel: The modern day struggle of the academic researcher. Annals of Neurology, 2015, 78, 667-669.	5.3	4
75	How clinical trials of myasthenia gravis can inform pre-clinical drug development. Experimental Neurology, 2015, 270, 78-81.	4.1	9
76	Bromodomain inhibitors regulate the C9ORF72 locus in ALS. Experimental Neurology, 2015, 271, 241-250.	4.1	25
77	Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurology, The, 2015, 14, 786-788.	10.2	38
78	Novel mutations expand the clinical spectrum of DYNC1H1 -associated spinal muscular atrophy. Neurology, 2015, 84, 668-679.	1.1	106
79	A Genome-Wide Association Study of Myasthenia Gravis. JAMA Neurology, 2015, 72, 396.	9.0	139
80	Mind the gap: The mismatch between clinical and imaging metrics in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 524-529.	1.7	65
81	Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy. Neurology, 2015, 85, 357-364.	1.1	157
82	Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis. Muscle and Nerve, 2015, 51, 14-18.	2.2	48
83	A case of familial ALS due to multi-system proteinopathy 1 and Huntington disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 124-126.	1.7	5
84	An 18F-FDG PET study of cervical muscle in parkinsonian anterocollis. Journal of the Neurological Sciences, 2014, 340, 174-177.	0.6	5
85	Electrical impedance myography correlates with standard measures of Als severity. Muscle and Nerve, 2014, 49, 441-443.	2.2	61
86	Thymectomy for non-thymomatous myasthenia gravis. The Cochrane Library, 2013, , CD008111.	2.8	36
87	C9ORF72 Intermediate Repeat Copies Are a Significant Risk Factor for Parkinson Disease. Annals of Human Genetics, 2013, 77, 351-363.	0.8	69
88	Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurology, The, 2013, 12, 310-322.	10.2	454
89	Repeat expansions in the C9ORF72 gene contribute to Alzheimer's disease in Caucasians. Neurobiology of Aging, 2013, 34, 1519.e5-1519.e12.	3.1	74
90	Reply. Muscle and Nerve, 2013, 47, 145-146.	2.2	1

#	Article	IF	Citations
91	Diagnostic Accuracy of Diffusion Tensor Imaging in Amyotrophic Lateral Sclerosis. Academic Radiology, 2013, 20, 1099-1106.	2.5	70
92	Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature, 2013, 495, 467-473.	27.8	1,249
93	Opportunity and innovation in studying preâ€symptomatic amyotrophic lateral sclerosis. Muscle and Nerve, 2013, 47, 629-631.	2.2	6
94	Motor neuron involvement in multisystem proteinopathy. Neurology, 2013, 80, 1874-1880.	1.1	85
95	Utility of Capture-Recapture Methodology to Assess Completeness of Amyotrophic Lateral Sclerosis Case Ascertainment. Neuroepidemiology, 2013, 40, 133-141.	2.3	21
96	ALS Untangled No. 20: The Deanna Protocol. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 319-323.	1.7	19
97	Presymptomatic studies in ALS. Neurology, 2012, 79, 1732-1739.	1.1	94
98	Mutational analysis of the VCP gene in Parkinson's disease. Neurobiology of Aging, 2012, 33, 209.e1-209.e2.	3.1	31
99	Valosin-containing protein (VCP) mutations in sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 2231.e1-2231.e6.	3.1	86
100	Enhancing translation: Guidelines for standard pre-clinical experiments in mdx mice. Neuromuscular Disorders, 2012, 22, 43-49.	0.6	67
101	Electrical impedance myography as a biomarker to assess ALS progression. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 439-445.	2.1	125
102	Design of the Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) trial. Annals of the New York Academy of Sciences, 2012, 1275, 17-22.	3.8	26
103	Clinical subtypes of anterocollis in parkinsonian syndromes. Journal of the Neurological Sciences, 2012, 315, 100-103.	0.6	16
104	Recommendations for myasthenia gravis clinical trials. Muscle and Nerve, 2012, 45, 909-917.	2.2	122
105	Preparing for a U.S. National ALS Registry: Lessons from a pilot project in the State of Georgia. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 130-135.	2.1	9
106	Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS. Neuron, 2011, 69, 397.	8.1	7
107	A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron, 2011, 72, 257-268.	8.1	3,833
108	Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. The Cochrane Library, 2011, , CD004030.	2.8	63

#	Article	IF	Citations
109	Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurology, The, 2011, 10, 400-403.	10.2	156
110	The Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: Have we put the cart before the horse?. Muscle and Nerve, 2011, 43, 461-463.	2.2	17
111	Impact of presymptomatic genetic testing for familial amyotrophic lateral sclerosis. Genetics in Medicine, 2011, 13, 342-348.	2.4	31
112	Magnetic resonance spectroscopy of the cervical cord in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 185-191.	2.1	47
113	Utility of axial and radial diffusivity from diffusion tensor MRI as markers of neurodegeneration in amyotrophic lateral sclerosis. Brain Research, 2010, 1348, 156-164.	2.2	105
114	HIV neuropathy in South Africans: Frequency, characteristics, and risk factors. Muscle and Nerve, 2010, 41, 599-606.	2.2	98
115	Pearls: Myasthenia. Seminars in Neurology, 2010, 30, 035-037.	1.4	1
116	Diffusion tensor imaging reveals regional differences in the cervical spinal cord in amyotrophic lateral sclerosis. NeuroImage, 2010, 53, 576-583.	4.2	77
117	Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS. Neuron, 2010, 68, 857-864.	8.1	1,100
118	Methodological Quality of Animal Studies of Neuroprotective Agents Currently in Phase II/III Acute Ischemic Stroke Trials. Stroke, 2009, 40, 577-581.	2.0	125
119	Developing reference data for nerve conduction studies: An application of quantile regression. Muscle and Nerve, 2009, 40, 763-771.	2.2	20
120	Reference data for commonly used sensory and motor nerve conduction studies. Muscle and Nerve, 2009, 40, 772-794.	2.2	47
121	Treatment for familial amyotrophic lateral sclerosis/motor neuron disease. The Cochrane Library, 2009, , CD006153.	2.8	4
122	Treatment of Pyridostigmine-Induced AV Block with Hyoscyamine in a Patient with Myasthenia Gravis. Journal of Cardiovascular Electrophysiology, 2008, 19, 214-216.	1.7	12
123	Treatment of ocular symptoms in myasthenia gravis. Neurology, 2008, 71, 1335-1341.	1.1	67
124	Levetiracetam Versus Carbamazepine Monotherapy for Partial Epilepsy in Children Less Than 16 Years of Age. Journal of Child Neurology, 2008, 23, 515-519.	1.4	25
125	Outcome Analysis in Clinical Trial Design for Acute Stroke: Physiciansâ€™ Attitudes and Choices. Cerebrovascular Diseases, 2008, 26, 156-162.	1.7	22
126	The muddle of mycophenolate mofetil in myasthenia. Neurology, 2008, 71, 390-391.	1.1	20

#	Article	IF	Citations
127	Evidence report: The medical treatment of ocular myasthenia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology [RETIRED]. Neurology, 2007, 68, 2144-2149.	1.1	132
128	SELECTING PROMISING ALS THERAPIES IN CLINICAL TRIALS. Neurology, 2007, 68, 1545-1546.	1.1	11
129	Diagnostic Accuracy of Thoracic Paraspinal Electromyography in Amyotrophic Lateral Sclerosis. Journal of Clinical Neurophysiology, 2007, 24, 298-300.	1.7	13
130	Clinical Equipoise and Treatment Decisions in Cervical Spondylotic Myelopathy. Canadian Journal of Neurological Sciences, 2007, 34, 47-52.	0.5	12
131	What zebras and mice can teach us about familial ALS. Neuromuscular Disorders, 2007, 17, 671-672.	0.6	3
132	The electromyographic diagnosis of amyotrophic lateral sclerosis: Does the evidence support the El Escorial criteria?. Muscle and Nerve, 2007, 35, 614-619.	2.2	36
133	Accuracy of repetitive nerve stimulation for diagnosis of the crampâ€“fasciculation syndrome. Muscle and Nerve, 2007, 35, 776-780.	2.2	38
134	Efficacy and Tolerability of Levetiracetam in Children Younger than 4 Years: A Retrospective Review. Epilepsia, 2007, 48, 1123-1127.	5.1	40
135	Lost in translation: Treatment trials in the SOD1 mouse and in human ALS. Neurobiology of Disease, 2007, 26, 1-13.	4.4	322
136	Medical and surgical treatment for ocular myasthenia. , 2006, , CD005081.		22
137	Preventing familial amyotrophic lateral sclerosis: Is a clinical trial feasible?. Journal of the Neurological Sciences, 2006, 251, 3-9.	0.6	19
138	A systematic review of diagnostic studies in myasthenia gravis. Neuromuscular Disorders, 2006, 16, 459-467.	0.6	232
139	Electrodiagnostic criteria for carpal tunnel syndrome in axonal polyneuropathy. Muscle and Nerve, 2006, 33, 747-752.	2.2	12
140	Concentric-needle single-fiber electromyography for the diagnosis of myasthenia gravis. Muscle and Nerve, 2006, 34, 163-168.	2.2	73
141	Distal symmetric polyneuropathy: Limitations of the proposed case definition. Muscle and Nerve, 2006, 34, 131-134.	2.2	6
142	Sural and radial sensory responses in healthy adults: Diagnostic implications for polyneuropathy. Muscle and Nerve, 2005, 31, 628-632.	2.2	55
143	Familial hemiplegic migraine: More than just a headache. Neurology, 2005, 64, 592-593.	1.1	7
144	The Spectrum of Cranial Neuropathy in Patients With Bellâ€™s Palsy. Archives of Internal Medicine, 2004, 164, 2383.	3.8	22

#	Article	IF	Citations
145	Repetitive nerve stimulation for the evaluation of peripheral nerve hyperexcitability. Journal of the Neurological Sciences, 2004, 221, 47-52.	0.6	26
146	Laminoplasty. Journal of Neurosurgery: Spine, 2004, 100, 399-400; author reply 400.	1.7	0
147	Interferon beta-1a and beta-1b for treatment of multiple sclerosis. Lancet, The, 2002, 360, 1428.	13.7	3
148	Immune-mediated peripheral neuropathies and voltage-gated sodiums channels. , 1999, 22, 108-110.		19
149	Autoimmune Neurological Disease. Trends in Neurosciences, 1996, 19, 301-302.	8.6	0